AKT1 and breast cancer: More interestingly, the Akt inhibitor Miltefosine, which has undergone multiple clinical trials and has been approved for treatment of breast cancer in Europe and parasite infections in other countries, was also able to inhibit viral production and cell survival in HIV-1 infected macrophages.